Expert interprets FDA guidance on social media

01/9/2012 | Wall Street Journal, The

Drugmakers should be cautious when soliciting patient testimonials because discussions of off-label use could run afoul of recent FDA guidance, says Dale Cooke, vice president and group director of regulatory review at marketing shop Digitas Health. Drugmakers should also be careful with blogging about clinical trials tied to unapproved uses and ensure that conversations about off-label uses are not in a public forum, he said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID